Compare Ishares Msci Italy ETF (EWI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs TG Therapeutics Inc — how do they compare? Ishares Msci Italy ETF trades at $56.3 (market cap $1.14B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 7.2× Ishares Msci Italy ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Ishares Msci Italy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 53 Days and TG Therapeutics Inc for 16 Days on average.
| EWI | TGTX | |
|---|---|---|
Market Cap | $1.14B | $8.16B |
Volume | 2,377,947 | 1,735,121 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $59.06 |
52-Week Low | $50.31 | $26.94 |
Typical Hold Time | 53 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI (iShares MSCI Italy ETF) trades at $56.32, down slightly by 0.05% with a bearish technical signal from moving averages and oscillators. The ETF provides concentrated exposure to Italian financials, utilities, and industrials, benefiting from sector consolidation and EU recovery investments. Recent news highlights European Central Bank rate hikes and energy price pressures affecting eurozone markets.
The outlook remains cautious due to technical bearish signals and macroeconomic headwinds from ECB tightening. Investment opportunity lies in Italy's banking consolidation and infrastructure spending, but risks include eurozone economic sentiment deterioration and persistent inflation concerns.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
